- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05018897
Strategic Disclosure Intervention for Suicide Attempt Survivors
Randomized Controlled Trial of a Strategic Disclosure Intervention for Suicide Attempt Survivors
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The estimated 1.3 million Americans who survive a suicide attempt suicide each year are at risk for ongoing suicide ideation, repeated suicide attempts, and ultimately dying by suicide. While suicide prevention often depends on people openly discussing suicidal thoughts and behaviors in order to get help for themselves or others, those who talk about their suicidality often face negative reactions from confidants. Stigmatizing responses in the form of stereotypes, prejudice, and discrimination may exacerbate symptoms and interfere with social relationships, employment opportunities, and help seeking. Feelings of shame and rejection are common experiences of suicide attempt survivors and the mere anticipation of rejection can encourage attempt survivors to maintain their silence.
Research suggests that suicide disclosure could help suicide attempt survivors in attaining needed care, expanding social support networks, strengthening relationships, and advancing coping strategies. However, few interventions are available to assist suicide attempt survivors in making critical disclosure decisions.
A peer-led strategic disclosure intervention (The 2Share Program), developed through a collaborative process with suicide attempt survivors, aids participants in: (a) evaluating the benefits and risks of disclosure; (b) considering ways to disclose; and (c) developing disclosure scripts. A pilot randomized controlled trial (RCT) with community-dwelling attempt survivors (n=38) found that intervention participants had significantly decreased depression and internalized stigma, and increased self-esteem as compared with the control group. However, this study was small and did not evaluate changes in suicidal thoughts and behaviors, help-seeking, or disclosure outcomes. The methodology was also limited in measuring longer term outcomes.
Given limitations of past research, the investigators propose a randomized controlled trial of the 2Share strategic disclosure program for community-dwelling suicide attempt survivors. The primary goal of this study is to evaluate the impact of the intervention on suicidal thoughts and behaviors and depression. Secondary goals are to examine intervention impact on stigma, disclosure, and psychosocial outcomes. A final goal of the project is to qualitatively examine participant experiences with disclosure over time.
The proposed research addresses the American Foundation for Suicide Prevention priority of determining what interventions are effective and what prevents individuals from engaging in suicidal behavior. The 2Share intervention is the first to address strategic disclosure in suicide attempt survivors, and this study will provide important data about disclosure that can ultimately aid in understanding suicide prevention.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Illinois
-
Chicago, Illinois, United States, 60616
- Illinois Institute of Technology
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 18 years or older
- self-reported diagnosis of mood disorder
- At least one lifetime suicide attempt
Exclusion Criteria:
- a self-reported suicide attempt within the last 3 months
- do have concerns about disclosure/ not willing to participate in program
- do not have email address
- do not have technical capability to connect to virtual platform
- cannot speak or read English
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: To Share or Not to Share
Manualized, peer-led, strategic disclosure program to guide participants in disclosing suicidality, held in group format, consisting of six sessions, each one hour in duration, once per week. Pre-survey, post-survey, and 3-month follow-up survey |
Strategic disclosure intervention to help participants evaluate the pros and cons of disclosing suicidality and provide guidance on best way to disclose to get needs met.
Six one-hour virtual sessions conducted weekly.
|
|
Active Comparator: Peer Support
Peer-led support group, held in group format, consisting of six sessions, each one hour in duration, once per week. Pre-survey, post-survey, and 3-month follow-up survey |
Peer-led support group for mood disorders.
Six one-hour virtual sessions conducted weekly.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change from Baseline in suicidality on the 9-item Suicidal Ideation Attributes Scale (SIDAS) at Week 6 and Week 19
Time Frame: Baseline, Week 6, Week 19
|
The SIDAS is a validated, self-reported instrument assessing suicidality over the past month.
Possible item scores range from 0 (no thoughts) to 10 (always) Change = (Week 6 Score - Baseline Score), (Week 19 - Baseline Score)
|
Baseline, Week 6, Week 19
|
|
Change from Baseline in depression on the 10- item Center for Epidemiologic Studies Depression Scale (CESD-10) at Week 6 and Week 19
Time Frame: Baseline, Week 6, Week 19
|
he CESD-10 is a validated, self-reported instrument assessing depression over the past week.
Possible item scores range from 1 (rarely to none of the time) to 4 (most or all of the time)
|
Baseline, Week 6, Week 19
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change from Baseline in internalized stigma on the 9- item Internalized Stigma of Suicide (ISSA) at Week 6 and Week 19
Time Frame: Baseline, Week 6, Week 19
|
The ISSA is a validated, self-reported instrument assessing internalized stigma.
Possible item scores range from 1 (strongly disagree) to 4 (strongly agree) Change = (Week 6 Score - Baseline Score), (Week 19 - Baseline Score)
|
Baseline, Week 6, Week 19
|
|
Change from Baseline in stigma-related stress on the 8- item Suicide Stigma Stress Scale (4S) at Week 6 and Week 19
Time Frame: Baseline, Week 6, Week 19
|
The 4S is a validated, self-reported instrument assessing stigma-related stress Possible item scores range from 1 (strongly disagree) to 7 (strongly agree) Change = (Week 6 Score - Baseline Score), (Week 19 - Baseline Score)
|
Baseline, Week 6, Week 19
|
|
Change from Baseline in self-esteem on the 10- item Rosenberg Self-Esteem (RSE) scale at Week 6 and Week 19
Time Frame: Baseline, Week 6, Week 19
|
The RSE is a validated, self-reported instrument assessing self-esteem.
Possible item scores range from 1 (strongly disagree) to 5 (strongly agree) Change = (Week 6 Score - Baseline Score), (Week 19 - Baseline Score)
|
Baseline, Week 6, Week 19
|
|
Change from Baseline in disclosure self-efficacy on the 2- item Disclosure Self-Efficacy (DSE) scale at Week 6 and Week 19
Time Frame: Baseline, Week 6, Week 19
|
The DSE is a validated, self-reported instrument assessing self-efficacy in disclosing suicidality.
Possible item scores range from 1 (not at all) to 7 (very much) Change = (Week 6 Score - Baseline Score), (Week 19 - Baseline Score)
|
Baseline, Week 6, Week 19
|
|
Change from Baseline in secrecy on the 14- item Self-Harm and Suicide Disclosure Scale (SHSDS) at Week 6 and Week 19
Time Frame: Baseline, Week 6, Week 19
|
The SHSDS scale is a validated, self-reported instrument assessing disclosure of suicidality. Items are answered yes/no and focus on disclosure of particular ideations and behaviors. Change = (Week 6 Score - Baseline Score), (Week 19 - Baseline Score) |
Baseline, Week 6, Week 19
|
|
Change from Baseline in secrecy on the 5- item Secrecy scale at Week 6 and Week 19
Time Frame: Baseline, Week 6, Week 19
|
The Secrecy scale is a validated, self-reported instrument assessing secrecy in disclosing suicidality.
Possible item scores range from 1 (strongly disagree) to 7 (strongly agree) Change = (Week 6 Score - Baseline Score), (Week 19 - Baseline Score)
|
Baseline, Week 6, Week 19
|
|
Change from Baseline in mental health seeking on the 3- item Mental Health Seeking Intention scale (MHSIS) at Week 6 and Week 19
Time Frame: Baseline, Week 6, Week 19
|
The MHSIS is a validated, self-reported instrument assessing intention to seek help.
Possible item scores range from 1 (extremely unlikely) to 7 (extremely likely) Change = (Week 6 Score - Baseline Score), (Week 19 - Baseline Score)
|
Baseline, Week 6, Week 19
|
|
Change from Baseline in quality of life on the 1- item quality of life scale at Week 6 and Week 19
Time Frame: Baseline, Week 6, Week 19
|
The question asks participants to rate their quality of life.
Possible scores range from 1 (very poor) to 5 (very good) Change = (Week 6 Score - Baseline Score), (Week 19 - Baseline Score)
|
Baseline, Week 6, Week 19
|
|
Change from Baseline in social support on the 8- item social support scale at Week 6 and Week 19
Time Frame: Baseline, Week 6, Week 19
|
The Social Support scale is the emotional subscale from the NIH Toolbox for Social Relationships and is a validated, self-reported instrument assessing social support.
Possible item scores range from 1 (never) to 5 (always) Change = (Week 6 Score - Baseline Score), (Week 19 - Baseline Score) Change = (Week 6 Score - Baseline Score), (Week 19 - Baseline Score)
|
Baseline, Week 6, Week 19
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- YIG-1-151-19
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Mood Disorders
-
Joliet Center for Clinical ResearchAbbottCompleted
-
VA Office of Research and DevelopmentCompleted
-
University of North Carolina, Chapel HillNational Institute of Mental Health (NIMH)Completed
-
University of Colorado, DenverCompletedMood Disorders | Irritable MoodUnited States
-
Hanyang UniversityDSM-Firmenich AGActive, not recruiting
-
National Institute of Mental Health (NIMH)Completed
-
Baskent UniversityZİYAFET UĞURLUCompletedDisaster; Personality | Disorder, MoodTurkey
-
Fayoum University HospitalCompletedKetamine-Induced Mood DisorderEgypt
-
Shanghai Mental Health CenterActive, not recruitingMood Disorders in Children and AdolescentsChina
-
Mayo ClinicCompletedMood Disorders in Children and AdolescentsUnited States
Clinical Trials on To Share or Not to Share
-
University of Alabama at BirminghamCompletedRespiratory Failure | Kidney Failure | Volume OverloadUnited States
-
The Cleveland ClinicCompletedNo Condition is the Focus of the StudyUnited States
-
University of Colorado, DenverDexCom, Inc.CompletedDiabetes Mellitus, Type IUnited States
-
Sir Run Run Shaw HospitalBiosense Webster, Inc.UnknownAtrial FibrillationChina
-
Hamilton Health Sciences CorporationUnknownBacteremia | InfectionCanada
-
Beijing Tongren HospitalCompletedType 2 Diabetic RetinopathyChina
-
Universidad Miguel Hernandez de ElcheMinisterio de Economía y Competitividad, SpainCompleted
-
Purdue UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Completed
-
International Centre for Diarrhoeal Disease Research...Stanford University; FHI 360; IEDCR, DGHS, BangladeshUnknown
-
University of MinnesotaCompletedPostoperative Nausea and VomitingUnited States